Diabetes and hypertension: pathogenesis, prevention and treatment (Q36035797)

11 August 2017

1 reference

title

Diabetes and hypertension: pathogenesis, prevention and treatment (English)

1 reference

11 August 2017

1 reference

Lewis Landsberg

1

1 reference

PubMed ID

15702616

11 August 2017

Mark Molitch

series ordinal

2

1 reference

11 August 2017

1 October 2004

1 reference

Clinical and Experimental Hypertension

11 August 2017

1 reference

11 August 2017

26

1 reference

11 August 2017

7-8

1 reference

11 August 2017

621-628

1 reference

Hypertension and diabetes

11 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

The relationship between glucose control and the development and progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

The treatment of hypertension in adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Ramipril and the development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCEH-200031945

21 January 2018

Identifiers

DOI

10.1081/CEH-200031945

1 reference

release_yvm3f436wrfjvgmjhduv6rd5zu

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yvm3f436wrfjvgmjhduv6rd5zu

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15702616

1 reference

PubMed ID

15702616